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Objective:
 
 To develop a decision-analytic model to as-
sess the cost-effectiveness of pergolide versus bro-
mocriptine in the treatment of Parkinson’s disease (PD).
 
Methods:
 
 A Markov decision-analytic model is used to
 
examine cost-effectiveness. The model ran for 20 cy-
cles of 6 months’ duration, and the patients progress
through six stages: Hoehn-Yahr stages 1–5 and death.
The transitional probabilities for each stage are derived
from a 12-year longitudinal study of patients with PD.
The costs in the model are derived from an expert panel
containing six Australian neurologists. A review of the
randomized controlled trials comparing the efficacy
and safety of pergolide versus bromocriptine was un-
dertaken. Five studies were identified, with four show-
ing that pergolide offers superior efficacy when com-
pared to bromocriptine. The Mizuno et al. (1995) study
was the largest of the controlled trials and also mea-
sured patient Hoehn-Yahr status before and after treat-
ment. This was identified as the most appropriate
source of relative efficacy data for the model. The
model examined various scenarios based on alternate
durations of superior clinical benefit with pergolide
compared to bromocriptine. The main analysis as-
sumed that patients in each arm of the model would
have identical Hoehn-Yahr status by the fifth year. Sen-
sitivity analysis was used to determine cost-effectiveness
in the case where the therapeutic benefit was of a
shorter duration.
 
Results:
 
 The Mizuno study indicates that an additional
19.09% of patients improved by at least one stage on
pergolide over bromocriptine, with an odds ratio of
2.26 (
 
p
 
 
 

 
 .01). The total health care cost per patient
over the 10-year period was $46,323 in the pergolide
treatment arm and $47,351 in the bromocriptine treat-
ment arm, an incremental saving of $1028. Patients
also spent extra time in Hoehn-Yahr stages 1, 2, and 3.
In sensitivity analyses, when the benefit from pergolide
expired between 6 months and 5 years after treatment
cessation, cost savings ranged from $68 to $2535.
 
Conclusion:
 
 Pergolide is cost saving and more effica-
cious than bromocriptine, and is therefore cost-effective.
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 bromocriptine, cost-effectiveness analysis,
decision-analytic modeling, economic evaluation, Par-
kinson’s disease, pergolide.
 
Introduction
 
Parkinson’s disease is a slowly progressive neuro-
logical disorder for which there is currently no
known cure. The condition involves substantial
morbidity and consumes a large amount of health
care resources. The first major breakthrough in
symptomatic treatment began with the suggestion
that a deficiency of dopamine in the central ner-
vous system might underlie the symptoms of the
disease [1]. This led to the administration of the do-
pamine precursor l-dopa to patients with the dis-
ease [2,3].
The efficacy of levodopa in Parkinson’s disease
(PD) decreases after several years [4]. This de-
creased efficacy has been related both to disease
progression and to the effects of levodopa itself.
The beneficial response to levodopa is lost steadily
over several years. Levodopa is symptomatic ther-
apy only, having no influence on the progressive
loss of nigral neurons. It is also accompanied by a
variety of acute and chronic side effects.
Dopamine receptor agonists, such as pergolide
and bromocriptine, have a longer half-life than
levodopa. These drugs achieve best results in pa-
tients with a decreasing response to levodopa.
This is because they bypass the degenerating SN
 
c
 
neurons and directly stimulate the postsynaptic
DA receptors (D
 
1
 
 and D
 
2
 
 receptors).
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Decision analysis is a tool that can be used to
estimate the possible cost and outcome implica-
tions of various interventions [5] in the treatment
of Parkinson’s disease. Economic evaluation can
employ both decision analysis and cost-effective-
ness analysis to aid in decisions regarding the
value for money offered by alternative interven-
tions [6]. This study employs these tools to exam-
ine the cost-effectiveness of pergolide versus bro-
mocriptine.
 
Methods
 
Decision-Analytic Model
 
The model is developed and applied to a number
of different scenarios. First, the cost-effectiveness
of treatment with pergolide versus bromocriptine
is examined in five scenarios where the initial
treatment benefit from pergolide is maintained for
6 months and 2, 3, 4, and 5 years. Second, com-
parative cost-effectiveness is evaluated where the
initial treatment benefit with pergolide is main-
tained over the full period of the model. It should
be noted, however, that the baseline results show
cost effectiveness when the initial treatment bene-
fit from pergolide is maintained for two years af-
ter treatment.
The analysis employed a Markov model, devel-
oped using the dedicated decision analysis soft-
ware Decision Analysis by TreeAge (Williamstown,
MA, USA) (DATA 3.5.4). A Markov model cap-
tures events over a period of time [7,8].
Patients are assumed to progress through six
discrete stages: Hoehn-Yahr stages 1–5 and death.
All Hoehn-Yahr stages are transitional states and
death is an absorbing stage. The model ran for 20
cycles of 6 months’ duration, and a discount rate
of 5% per annum was applied to all costs and out-
comes. The evaluation takes a health care system
perspective.
 
Transition Probabilities
 
The transition probabilities for each Hoehn-Yahr
stage are derived from a 12-year longitudinal
study of patients with Parkinson’s disease [Hely
M, Morris J. Personal communication regarding
database at Westmead Hospital, Westmead, Aus-
tralia, 1998]. There were 149 patients initiated into
the open-label cohort study. The constant proba-
bility of patients moving from each stage on the
Hoehn-Yahr scale to an alternate stage was calcu-
lated for each year between baseline and year 10.
The initial probabilities of entering each state for
patients at baseline were also derived from the lon-
gitudinal study. The transition probabilities in the
bromocriptine arm of the model were derived from
the longitudinal database (i.e., the annual proba-
bility in the database of moving from Hoehn-Yahr
stage 2 to Hoehn-Yahr stage 3 was 0.15, con-
verted to a 6-month probability of 0.075, which
was then the probability assigned to the model; Ta-
ble 5). The pergolide transition probabilities were
adjusted in the initial period using the results of the
Mizuno trial [ 9].
 
Costs
 
Costs in the model are based on a survey of an ex-
pert panel that comprised six senior Australian
neurologists. They indicated the pattern of treat-
ment for patients in each stage of the Hoehn-Yahr
scale. A combination of charges and cost data are
used to derive an average cost for a year of treat-
ment in each Hoehn-Yahr stage. For the purposes
of this analysis these costs are then converted to
6-monthly costs (expressed in 1998 ⁄ 99 Australian
dollars). In the case of nursing home stays, the
probability of admission is derived from the longi-
tudinal study.
 
Pergolide versus Bromocriptine
 
Difference in Efficacy Between the Two Thera-
pies.
 
The search for clinical papers was designed
to find all randomized controlled trials examining
the difference in safety and efficacy with pergolide
compared to bromocriptine. Medline and EMBASE
databases were surveyed for the period between
January 1980 and June 1999. Five randomized con-
trolled studies were identified [9–13].
Four of the five studies indicated that pergolide
provided superior efficacy when compared to bro-
mocriptine [9,11–13]. This confirmed that in the
model, outcomes with pergolide should be supe-
rior to bromocriptine.
In order to undertake any economic evaluation,
clinically significant and statistically significant di-
chotomous variables are required. Also, the clinical
expert panel suggested that response as measured
by changes in status on the Hoehn-Yahr scale rep-
resented clinically significant responses that could
alter long-term patient outcomes. For these reasons,
the Mizuno et al. [9] study was used as the basis
of the relative efficacy differences in the model.
The Mizuno et al. [9] study measured Hoehn-
Yahr scores at baseline and last study visit. This
was a 26-week, double-blind, randomized con-
trolled trial that included 192 patients who were
 310
 
Davey et al.
 
treated with adjunctive levodopa alongside either
pergolide or bromocriptine. This was the largest
of the controlled trials and a well-designed study.
The published study results showed significantly
more patients were in the Hoehn-Yahr stage in the
off period of wearing off (
 
p
 
 
 

 
 .01). Another statis-
tically significant difference that favored pergolide
was an increase in the number of patients who
gained improvement on the modified rating scale
of Mizuno et al. [9]. The sponsor provided indi-
vidual patient data from this trial to allow the
proportion of patients gaining an improvement in
Hoehn-Yahr to be determined. Mizuno et al. col-
lected Hoehn-Yahr scores at both baseline and 26
weeks. The risk difference was determined so it
could be used in economic evaluation to estimate
the absolute benefit from treatment. The relative
risk and odds ratios were also determined.
The results from the other studies were broadly
consistent with the Mizuno et al. trial. However,
these were not used in the economic evaluation. A
double-blind, randomized crossover study was un-
dertaken by Bonnet et al. [12] in 12 patients with
fluctuating motor disability and levodopa-induced
dyskinesia. The duration of the on period was signif-
icantly longer with pergolide (
 
p
 
 
 

 
 .02). The global
therapeutic response on parkinsonian motor disabil-
ity and fluctuations was significantly superior with
pergolide than with bromocriptine (
 
p
 
 
 

 
 .004). No
other statistically significant differences were found.
In contrast to the other controlled trials, the Le-
Witt et al. [10] study found bromocriptine to be
equal to or slightly superior to pergolide. It was a
double-blind randomized crossover study in 27
patients. Each treatment period ranged from 7 to
10 weeks. The authors found the two agents to be
similar overall, although handwriting speed was
faster with bromocriptine than with pergolide
(
 
p
 
 
 

 
 .009). Thus, this study produced a contrary
finding to the other controlled studies in that per-
golide was found not to be superior to bromocrip-
tine. A possible explanation was that there may
have been a selection bias resulting from the fact
that 15 of the 27 patients in the study had been
previously managed on bromocriptine, either as
part of a previous crossover study or as treatment.
Logically, patients who failed to gain a therapeutic
effect or dropped out because of side effects would
be unlikely to enter into a trial where they could
possibly be randomized to bromocriptine. There-
fore, these patients would probably be bromocrip-
tine responders, and this may bias the results.
Pezzoli et al. [11] reported the results of a ran-
domized controlled crossover study in 68 patients
 
with a duration of 26 weeks. The study found per-
golide to be significantly superior compared to
bromocriptine on the New York University Par-
kinson’s Disease Scale (NYUPDS). The aggregate
score with pergolide was 139.7 
 

 
 7.4, and with
bromocriptine, 162.7 
 

 
 7.4 (
 
p
 
 
 

 
 .01). Pergolide
was also superior with regard to Clinical Global
Impression-II (CGI-II) (
 
p
 
 
 

 
 .0035), and the Pa-
tient Global Impression-I (PGI-I) (
 
p
 
 
 

 
 .0006) and
Patient Global Impression-II (PGI-II) (
 
p
 
 
 

 
 .002)
scales. There were no other differences detected
between the two therapies.
Boas et al. [13] reported a 24-week randomized
open-label crossover study. Pergolide treatment
was associated with statistically significantly greater
dose-sparing capacity (
 
p
 
 
 

 
 .01) when compared with
bromocriptine. With regard to scores on the Unified
Parkinson’s Disease Rating Scale (UPDRS), improve-
ments in motor examination scores were signifi-
cantly greater with pergolide (
 
p
 
 
 

 
 .01). No other
statistically significant differences were observed
between the two therapies.
 
Difference Between Two Groups at Entry into the
Model and Period of Relative Clinical Benefit.
 
It was assumed that patients entering the model in
the pergolide branch reflect the absolute risk dif-
ference in the trial; that is, 19.09% of patients en-
ter the model at a higher Hoehn-Yahr stage in the
pergolide arm compared to the bromocriptine arm.
The model assumed that patients started in the
pergolide group with a superior Hoehn-Yahr score
compared to patients in the bromocriptine group.
This reflected the absolute risk difference in the
Mizuno trial (19.09%). Also, in the model an equal
number of patients shift from Hoehn-Yahr stage 3
to stage 2 as shift from Hoehn-Yahr stage 2 to
stage 1. In the base case scenario, the duration of
superior relative efficacy is assumed to last up to 2
years, as estimated by clinical experts.
After the second year following treatment, the
probability of patients’ being in each Hoehn-Yahr
stage is equal for bromocriptine and pergolide
branches. This meant that pergolide-treated pa-
tients progress at a faster rate between 1.5 and 2
years after treatment and at the same rate as bro-
mocriptine patients thereafter. Alternative scenar-
ios are presented showing the effect of this conver-
gence during the first 6 months and the third,
fourth, and fifth years after treatment. The final
scenario demonstrates the cost-effectiveness of per-
golide when no convergence occurs and the initial
difference between pergolide and bromocriptine is
maintained over the 10-year modeled period.
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It is assumed that the cost of bromocriptine and
pergolide is incurred for 6 months only. This short
duration of treatment in the model is intended to
maintain a link between trial inputs (drug therapy)
and trial outputs (clinical improvement). Doses were
calculated from the average used in the Mizuno
trial.
The duration of the model was 10 years. This
period was chosen because it represents the period
over which a large proportion of patients progress
to end stage Parkinson’s disease.
 
Results
 
Pergolide versus Bromocriptine
 
Incremental costs are presented in Table 1. The to-
tal per-patient cost of treatment when the two
branches converge after the end of the second year
is $46,323 in the pergolide treatment arm and
$47,351 in the bromocriptine treatment arm. Thus,
 
Table 1
 
Incremental savings (in Australian dollars)
 
Base case: Pergolide benefit expires at end of second year after
treatment
Treatment arm Cost ($)*
Pergolide 46,323
Bromocriptine 47,351
Incremental savings 1,028
Alternative 1: Pergolide benefit does not expire during 
model period
Pergolide 44,659
Bromocriptine 47,351
Incremental savings 2,782
Alternative 2: Pergolide benefit expires 6 months 
after treatment
Pergolide 47,283
Bromocriptine 47,351
Incremental savings 68
Alternative 3: Pergolide benefit expires at end of third
year after treatment
Pergolide 45,699
Bromocriptine 47,351
Incremental savings 1,652
Alternative 4: Pergolide benefit expires at end of fourth 
year after treatment
Pergolide 45,177
Bromocriptine 47,351
Incremental savings 2,174
Alternative 5: Pergolide benefit expires at end of fifth
year after treatment
Pergolide 44,816
Bromocriptine 47,351
Incremental savings 2,535
 
*Discounted at 5%.
Figure 1 Pergolide cost savings by year of treatment benefit
erosion.
 
Table 2
 
Cost components (and unit costs) for each Hoehn-Yahr stage (in Australian dollars)
 
Hoehn-Yahr Stage
Cost ($ unit costs) 1 2 3 4 5
Neurologist ($32.50) 9.75 19.50 35.75 42.25 15.60
General practitioner ($45.30) 29.45 63.42 117.78 156.29 566.25
Psychologist ($57.00) 2.85 3.14 5.70 7.41 3.71
Occupational therapist ($36.00) 1.80 1.98 3.60 6.84 4.50
Physiotherapist ($28.00) 1.40 23.10 37.10 82.60 105.00
Speech pathologist ($31.00) 1.55 3.10 5.12 16.28 9.77
Total medical 46.80 114.24 205.05 311.66 704.82
AN-DRG*–assessment ($4,951.00) 1,856.63 — — 1,633.83 —
AN-DRG*–drug changes ($4,951.00) — 618.88 816.92 2,475.50 618.88
AN-DRG*–side effects ($4,951.00) — — 618.88 816.92 1,237.75
Total hospital 1,856.63 618.88 1,435.79 4,926.25 1,856.63
Levodopa/carbidopa ($39.59) 78.03 195.08 260.11 346.81 390.16
Levodopa/benserazide ($36.51) 47.98 119.94 159.92 213.22 239.87
Benzhexol hydrochloride ($10.88) 1.49 2.98 2.98 2.98 2.24
Selegeline hydrochloride ($64.34) — 352.26 469.68 774.98 704.53
Total support drugs 127.50 670.26 892.68 1,337.98 1,336.79
Nursing home ($27,079.35) — 135.40 406.19 3,655.71 12,591.90
Total 2,030.92 1,538.76 2,939.71 10,231.60 16,490.13
 
*Australian National Diagnosis Related Groups (version 3.1).
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the pergolide arm is associated with cost savings
of $1028 per patient over the total period.
Table 1 also displays the incremental costs as-
sociated with the alternative scenarios. It should be
noted that pergolide remains cost saving compared
to bromocriptine under every scenario, even where
all of the treatment benefit expires within 6 months
of treatment cessation (Alternative 2). The cost
savings from pergolide for each convergence sce-
nario are also displayed in Figure 1. When it is as-
sumed that no convergence occurs, and the initial
benefits of pergolide remain throughout the model
period, pergolide offers greater cost savings than
under the baseline assumptions.
The costing is based on estimates of unit cost
and annual frequency of resource use provided
by an expert panel of clinicians. Costs for each
6-month period spent in Hoehn-Yahr stages 1, 2, 3,
4, and 5 are estimated to be $2,031, $1,539, $2,940,
$10,232 and $16,490, respectively. The various re-
sources that make up these cost figures and their as-
sociated unit costs are presented in Table 2.
The doses of dopaminergic receptor agonist,
based on the Mizuno et al. [9] trial doses, were
1.24 mg for pergolide and 14.6 mg for bromocrip-
tine. The costs of pergolide and bromocriptine
therapy are estimated at $662.06 and $622.03, re-
spectively, for 6 months of treatment.
 
Table 3
 
Time in each Hoehn-Yahr stage
 
Base case: Pergolide benefit expires at end of second year after 
treatment
Stage
Time in stage: 
Pergolide*
Time in stage: 
Bromocriptine*
Hoehn-Yahr 1 0.54 0.42
Hoehn-Yahr 2 2.91 2.77
Hoehn-Yahr 3 1.59 1.81
Hoehn-Yahr 4 0.94 0.97
Hoehn-Yahr 5 0.18 0.18
Death 1.43 1.43
Hoehn-Yahr 1, 2, & 3 5.04 5.00
Alternative 1: Pergolide benefit
does not expire during 
model period
Hoehn-Yahr 1 0.65 0.42
Hoehn-Yahr 2 3.14 2.77
Hoehn-Yahr 3 1.52 1.81
Hoehn-Yahr 4 0.85 0.97
Hoehn-Yahr 5 0.16 0.18
Death 1.26 1.43
Hoehn-Yahr 1, 2, & 3 5.31 5.00
Alternative 2: Pergolide benefit
expires 6 months after 
treatment
Hoehn-Yahr 1 0.44 0.42
Hoehn-Yahr 2 2.80 2.77
Hoehn-Yahr 3 1.76 1.81
Hoehn-Yahr 4 0.97 0.97
Hoehn-Yahr 5 0.18 0.18
Death 1.43 1.43
Hoehn-Yahr 1, 2, & 3 5.00 5.00
Alternative 3: Pergolide benefit
expires at end of third 
year after treatment
Hoehn-Yahr 1 0.57 0.42
Hoehn-Yahr 2 2.96 2.77
Hoehn-Yahr 3 1.55 1.81
Hoehn-Yahr 4 0.91 0.97
Hoehn-Yahr 5 0.18 0.18
Death 1.41 1.43
Hoehn-Yahr 1, 2, & 3 5.08 5.00
Alternative 4: Pergolide benefit
expires at end of fourth
year after treatment
Hoehn-Yahr 1 0.60 0.42
Hoehn-Yahr 2 3.01 2.77
Hoehn-Yahr 3 1.52 1.81
Hoehn-Yahr 4 0.89 0.97
Hoehn-Yahr 5 0.17 0.18
Death 1.40 1.43
Hoehn-Yahr 1, 2, & 3 5.13 5.00
Alternative 5: Pergolide benefit
expires at end of fifth year
after treatment
Hoehn-Yahr 1 0.62 0.42
Hoehn-Yahr 2 3.04 2.77
Hoehn-Yahr 3 1.51 1.81
Hoehn-Yahr 4 0.88 0.97
Hoehn-Yahr 5 0.17 0.18
Death 1.38 1.43
Hoehn-Yahr 1, 2 & 3 5.17 5.00
 
*Discounted at 5%.
Figure 2 Decision tree
Markov node 
Decision node 
Absorbing state 
Choice node 
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The primary outcome of therapy is maximiza-
tion of time in Hoehn-Yahr stages 1, 2, and 3. Ta-
ble 3 shows the outcomes of therapy. When con-
vergence occurs at the end of the second year
following cessation of therapy, patients in the per-
golide arm spend 0.04 more years in Hoehn-Yahr
stages 1, 2, and 3 (and 0.26 more years in Hoehn-
Yahr stages 1 and 2) than do patients in the bro-
mocriptine arm. Again, pergolide is equally or
more effective than bromocriptine, regardless of
when convergence between the two occurs. When
no convergence occurs, the extra time in stages 1,
2, and 3 is 0.31 years.
Table 4 displays the results of the Mizuno et al.
[9] trial, which formed the basis of this evaluation.
The endpoint in the trial was the number of pa-
tients improving at least one stage on the Hoehn-
Yahr scale. This was considered by the panel of
clinical experts to be a clinically significant end-
point for therapy. An additional 19.09% of pa-
tients improved at least one stage on pergolide
when compared to patients on bromocriptine (
 
p
 
 
 

 
.01). The odds ratio was 2.26 (
 
p
 
 
 

 
 .01).
The structure of the decision tree used to model
the cost-effectiveness of pergolide versus bromo-
criptine is shown in Figures 2 and 3. The tree shown
in Figure 2 demonstrates the start of the Markov
processes and shows the probability of entry into
different health states. This is complemented by Fig-
ure 3, which shows possible transitions between
these health states.
The transition probabilities applied in the model
are shown in Table 5. Each probability is derived
from the Australian longitudinal study.
The trial-based evidence used in the model indi-
cates that the additional drug cost of pergolide for
a 6-month period is $40.03 ($662.06–622.03).
The health benefits amount to 19.09% of patients
gaining an improvement in the Hoehn-Yahr stage.
This suggests a trial-based incremental cost-effec-
tiveness ratio of $209.69 per patient gaining an
improvement in Hoehn-Yahr stage. Thus, based on
the strongest level of evidence, pergolide would ap-
pear to be cost-effective compared to bromocriptine.
 
Sensitivity Analysis.
 
Table 6 shows the sensitivity
analysis for the model. Varying the discount rate
from 0% to 10% alters the incremental cost sav-
ings only slightly to $1077 and $983, respectively.
Similarly, the variation in discount rate results in
only a very small variation in incremental out-
comes (0.039 years to 0.044 years).
It is also customary to test the sensitivity of re-
sults of the major cost data used in the model. Ac-
cordingly, the cost of each Hoehn-Yahr stage is
varied by 25% above and below the figure used in
the model. This has little impact on cost saving,
with the extreme values still showing savings of
$700 and $1350 per patient in the pergolide arm.
This is not surprising, given the similar amount of
time spent in the high-cost Hoehn-Yahr stages
(stages 4 and 5) by patients in both treatment
groups.
 
Discussion
 
The application of decision analysis and cost-
effectiveness analysis to the consideration of the
treatment of Parkinson’s disease provides useful in-
sights. Primarily, therapies that delay the progres-
sion of the condition can lead to cost savings for the
health care system and will improve the patient’s
quality of life. More controversially, it is possible
that delayed progression may lead to increased sur-
 
Table 4
 
Trial results [9]—fixed effects
 
Statistic Pergolide Improved Bromocriptine Improved Result Lower 95% CI Higher 95% CI
Odds ratio 45/93 (48%) 29/99 (29% ) 2.26 1.25 4.10
Risk difference 0.1909 0.0555 0.3264
 
P
 
 
 

 
 .01.
Figure 3 Transition-state diagram
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vival. An appropriate investigation of this relation-
ship is beyond the scope of the methodology used
in this paper and relies more on further long-term
controlled clinical trials. This study demonstrates
that savings brought about by a one-time improve-
ment in the health status of patients are likely to be
relatively substantial. The saving with pergolide
represents approximately $1028 per patient.
The decision analysis explicitly integrated all of
the relevant available data. The model could be
usefully employed to examine the cost and outcome
implications of a broad range of interventions. For
example, a new intervention that changes the pro-
gression of Parkinson’s disease could be analyzed.
Changes to the cost of treating patients could also
be examined using the model, as demonstrated in
the sensitivity analysis.
Cost-effectiveness analysis illustrates the value for
money offered by alternative interventions. Thus,
with this information, decision makers can make
better-informed decisions regarding the opportunity
cost (the value of forgone spending in alternative ar-
eas) of additional expenditures. The Mizuno trial in-
dicated that more patients improve on the Hoehn-
Yahr scale with pergolide than with bromocriptine.
One particular difficulty involved the extrapola-
tion of improvements in Hoehn-Yahr from 6-month
clinical studies to the 10-year model. First, one
must always be cautious about such long extrapo-
lations of short-term studies. In this analysis, how-
ever, we were aided by the fact that the extrapola-
tions were based on empirical data from a 10-year
longitudinal study, and so the sources of potential
extrapolation error were diminished. Second, it
could be argued that progression in the pergolide
group would be faster than in the bromocriptine
group even though patients on pergolide entered
the model with lower Hoehn-Yahr scores. How-
 
Table 5
 
Transition probabilities—pergolide benefit 
expires after second year following treatment cessation*
 
Probability of entering stage 
during 6-month period
Commencing stage H-Y 1 H-Y 2 H-Y 3 H-Y 4 H-Y 5 Death
H-Y stage 1 0.80 0.175 0.02 0.00 0.00 0.005
H-Y stage 2 0.025 0.87 0.075 0.02 0.00 0.01
H-Y stage 3 0.00 0.075 0.815 0.085 0.005 0.02
H-Y stage 4 0.00 0.02 0.02 0.835 0.055 0.07
H-Y stage 5 0.00 0.00 0.01 0.025 0.74 0.225
Death 1.00
Pergolide 2.5–3 years
Probability of entering stage 
during 6-month period
Commencing stage H-Y 1 H-Y 2 H-Y 3 H-Y 4 H-Y 5 Death
H-Y stage 1 0.430 0.545 0.02 0.00 0.00 0.005
H-Y stage 2 0.025 0.6683 0.2767 0.02 0.00 0.01
H-Y stage 3 0.00 0.075 0.6142 0.2858 0.005 0.02
H-Y stage 4 0.00 0.02 0.02 0.6163 0.175 0.1687
H-Y stage 5 0.00 0.00 0.01 0.025 0.06 0.905
Death 1.00
 
*Pergolide 0–2.5, 3–10 years; bromocriptine 0–10 years.
 
Table 6
 
Sensitivity analysis for base scenario—pergolide benefit expires after second year following treatment cessation (in 
Australian dollars)
 
Sensitivity analysis Results
Discount rate (baseline 5%) $ Incremental cost savings ($) Incremental outcomes (life years)
0% 1,076.65 0.044*
10% 982.52 0.039
Cost Hoehn-Yahr Stage 1
25% Lower 1,523.19 1,147.94
 
†
 
25% Upper 2,539.65 907.31
 
†
 
Cost Hoehn-Yahr Stage 2
25% Lower 1,154.07 1,131.12
25% Upper 1,923.45 924.36
Cost Hoehn-Yahr Stage 3
25% Lower 2,204.78 716.79
25% Upper 3,674.63 1,338.70
Cost Hoehn-Yahr Stage 4
25% Lower 7,673.70 872.74
25% Upper 12,789.50 1,182.74
Cost Hoehn-Yahr Stage 5
25% Lower 12,367.60 1,003.18
25% Upper 20,612.67 1,052.30
All lower costs 760.80
All upper costs 1,294.45
 
*Outcome reflects number of extra years in Hoehn-Yahr stages 1, 2, and 3.
 
†
 
Outcome results ($) unchanged from baseline.
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ever, there is no evidence to support this assertion.
The approach taken in our base model assumes
that all the relative benefits of pergolide dissipate
by the end of the second year after therapy. There-
fore, for the final 8 years of the model, presence in
and transition between each health state is the
same for pergolide and bromocriptine patients. It
is possible that the relative benefits will last much
longer than this. As a result, modeling convergence
by the end of the second year following treatment
cessation represents a conservative approach.
An important limitation of this model is that it
does not incorporate considerations of quality of
life. Given that there is such a large difference be-
tween the various Hoehn-Yahr stages, a valuation
of quality of life would be useful. The model im-
plicitly assumed that the quality of life of a patient
in Hoehn-Yahr stages 1, 2, or 3 was the same.
Therefore, the model would have been improved if
utility weights had been derived [5]. This would
allow the derivation of Quality-Adjusted Life Years,
which are commonly used to compare the cost-
effectiveness of health care interventions in a vari-
ety of therapeutic areas [14].
From our analysis, pergolide is shown to be
cost saving and more efficacious than bromocrip-
tine. This is because pergolide offers clinical bene-
fits at a small additional cost of therapy. This
shows that a therapy with a higher purchase price
can result in cheaper health care costs if down-
stream health care costs are avoided.
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